Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

skin check

Bristol-Myers Squibb (BMS) building

BMS adds another EU indication to Opdivo’s growing list

Wins European licence to treat high-risk advanced melanoma

- PMLiVE

Evotec invests €15m in AI firm Exscientia

Funds will help the Scottish group accelerate growth

Breathing data

Novartis’ new CEO-designate points to an evolutionary leap

AI’s potential in the pharma life cycle

At a time that the future of life sciences is being hotly debated, the opportunity for the industry to refine and expand its role is an important one to take...

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

Why AI might be the rep’s best friend

When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Anthill Agency

Almirall looks to crowdsource new skin health treatments

Launches open innovation platform AlmirallShare

- PMLiVE

PharmaLex strikes up AI collaboration with Volv

The duo will develop pharmacovigilance products and services

Perfecting the pharmaceutical pipeline with AI

How AI can transform the way we identify and validate research

- PMLiVE

Is it time we stopped talking about adherence?

Delivering a fresh approach to patient care

Bristol-Myers Squibb (BMS) building

Opdivo tops Yervoy in adjuvant melanoma trial

BMS’ nivolumab reduced the recurrence rate of melanoma compared to Yervoy

- PMLiVE

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links